Navigation Links
Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
Date:4/27/2010

SAN DIEGO, April 27, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank 35th Annual Healthcare Conference in Boston on Tuesday, May 4, 2010 at 10:40 a.m. ET / 7:40 a.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and a recording will be made available on the Web site following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 HubCast® ... Supply Chain, today announced the expansion of its Global ... color-matched print to 850 the world’s largest cities across ... Chain extends to 137 countries providing global enterprises ease, ... print procurement process from online order to real-world delivery ...
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the ... under Chapter 11 of the U.S. Bankruptcy Code in the ... , Santa Ana division (the "Bankruptcy ... are expected to be jointly administered. The Company ... sale process, for all or substantially all of its assets ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Thingee to present at 11th Annual Synergistix Users Conference 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... Calif., Oct. 5 Sigma-Aldrich Corporation (Nasdaq: ... SGMO ) today announced a major expansion of ... rights to develop and distribute zinc finger DNA ... of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights ...
... Abidance Consulting and ... way to protect their facilities both physically and logically from accidental and intentional intrusions. ... Houston, TX (PRWEB) October 5, ... workshops around the country in the next 12 months. These workshops will be targeting physical ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") ... of the warrant indenture for those warrants issued on ... of the broker warrant certificates for the broker warrants ... the required written notice to holders of such warrants ...
Cached Biology Technology:Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 2Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 3Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 4Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date 2
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... at the National Institutes of Health and the Center ... of intent creating a Global Alliance for Pharmacogenomics. The ... individual responses to medicines, including rare and dangerous side ... doctors optimize the safety and effectiveness of drugs for ...
... the GSI accelerator facility to assess radiation risks that astronauts ... selected because its accelerator is the only one in Europe ... space. To determine possible health risks of manned space flights, ... the effects of ion beams in human cells and organs. ...
... of epilepsy, researchers found one of the bodys own ... pathway in the brain that increases production of a ... Researchers say this may explain why approximately 30 percent ... medications. The study, conducted by researchers at the ...
Cached Biology News:Launching a global alliance for pharmacogenomics 2Missions to Mars 2Brain study may lead to improved epilepsy treatments 2
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Dnase and Rnase free...
...
Biology Products: